$0.56 EPS Expected for Heska Corporation (HSKA)

February 23, 2018 - By Dolores Ford

 $0.56 EPS Expected for Heska Corporation (HSKA)
Investors sentiment increased to 1.26 in Q3 2017. Its up 0.01, from 1.25 in 2017Q2. It is positive, as 16 investors sold Heska Corporation shares while 37 reduced holdings. 24 funds opened positions while 43 raised stakes. 5.53 million shares or 0.49% more from 5.51 million shares in 2017Q2 were reported.
Tiaa Cref Invest Mgmt Ltd Company has invested 0% in Heska Corporation (NASDAQ:HSKA). Perceptive Limited Company stated it has 0.02% in Heska Corporation (NASDAQ:HSKA). Secor Advsr L P stated it has 0.09% in Heska Corporation (NASDAQ:HSKA). Moreover, Royal Commercial Bank Of Canada has 0% invested in Heska Corporation (NASDAQ:HSKA) for 1,388 shares. Martingale Asset Management Lp holds 0.03% or 23,302 shares in its portfolio. Bancorporation Of Montreal Can invested 0% of its portfolio in Heska Corporation (NASDAQ:HSKA). Neuberger Berman Grp Llc accumulated 603,469 shares. Colorado-based Alps Advisors has invested 0% in Heska Corporation (NASDAQ:HSKA). Moreover, Wellington Mgmt Grp Inc Incorporated Ltd Liability Partnership has 0% invested in Heska Corporation (NASDAQ:HSKA). D E Shaw & Com reported 0% of its portfolio in Heska Corporation (NASDAQ:HSKA). Moreover, State Street Corporation has 0% invested in Heska Corporation (NASDAQ:HSKA). 23,549 were accumulated by Clarivest Asset Management Limited Liability Com. 15,590 are owned by Alliancebernstein Lp. Mason Street Advsrs Ltd Liability Co holds 1,647 shares. 11,670 were accumulated by Legal General Group Public Limited Liability Corp.

Since August 30, 2017, it had 0 insider buys, and 2 selling transactions for $348,184 activity. McMahon John sold 2,608 shares worth $263,857.

Analysts expect Heska Corporation (NASDAQ:HSKA) to report $0.56 EPS on February, 28 before the open.They anticipate $0.10 EPS change or 21.74 % from last quarter’s $0.46 EPS. HSKA’s profit would be $4.06 million giving it 26.77 P/E if the $0.56 EPS is correct. After having $0.40 EPS previously, Heska Corporation’s analysts see 40.00 % EPS growth. The stock decreased 1.70% or $1.04 during the last trading session, reaching $59.96. About 59,755 shares traded. Heska Corporation (NASDAQ:HSKA) has risen 162.64% since February 23, 2017 and is uptrending. It has outperformed by 145.94% the S&P500.

Heska Corporation (NASDAQ:HSKA) Ratings Coverage

Among 8 analysts covering Heska Corp (NASDAQ:HSKA), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Heska Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. CL King downgraded the stock to “Neutral” rating in Thursday, January 26 report. The firm earned “Neutral” rating on Friday, April 1 by CL King. The firm earned “Buy” rating on Wednesday, March 1 by Benchmark. Benchmark initiated it with “Buy” rating and $78 target in Tuesday, November 29 report. The stock has “Hold” rating by Gabelli on Tuesday, August 1. The rating was downgraded by Gabelli to “Hold” on Thursday, August 4. The stock of Heska Corporation (NASDAQ:HSKA) earned “Hold” rating by TheStreet on Tuesday, August 25.

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company has market cap of $434.34 million. It operates through two divisions, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. It has a 31.44 P/E ratio. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.